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in this study without a matched surgical cohort undergoing
sublobar resection.
We recognize that this is a prospective, observational
study with limited patient numbers and relatively short fol-
low-up. This is also a highly selected patient population sub-
ject to the institutional biases of the multidisciplinary team.
Unlike previous series, we did not use multiple RFA systems
to deliver treatments. Because 3 patients received conven-
tional XRT to lesions for which RFA had failed, firm conclu-
sions regarding outcome in these cases is confounded.
In summary, experience with RFA for stage I NSCLC is
accumulating. Intermediate results are encouraging and rival
the local control observed with conventional XRT. As newer
noninvasive alternatives emerge for medically inoperable
tumors, our ability to accurately stage cancers becomes
even more critical. One should emphasize the need for tho-
racic surgeons to be involved in the clinical decisions for
these difficult cases. Invasive staging modalities, such as
mediastinoscopy and endobronchial or endoesophageal
ultrasonography should be used for biopsy of suspect hilar
or mediastinal lymph nodes. Determination of response to
treatment and detection of local failure require careful
evaluation with anatomic (diagnostic CT) and functional
(PET) imaging by institutions experienced with RFA.
We acknowledge our research coordinators, Emily Nohrden,
MPH, and JoAnne Martino, RN, for compiling some of the data.
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Dr Neil A. Christie (Pittsburgh, Pa). Lanuti and colleagues at
Massachusetts General Hospital should be commended for the ex-
ecution of the study. They are first to be commended for having tho-
racic surgeons participating both in the selection of these patients
and also in the application of the treatment, because it is important
that surgeons be involved. They are second to be commended both
for carefully evaluating their results and for presenting them now.
These newer ablative therapies, such as RFA and stereotactic radio-
surgery, are being widely promoted by radiologists and radiation
oncologists as alternative nonoperative but potentially curative
therapies for early-stage lung cancer. Earlier this week, Dr Roth
presented a multi-institutional study in which patients with opera-
ble early-stage lung cancer were randomly assigned to undergo ei-
ther surgery or ablative therapy with stereotactic radiosurgery for
lung cancers as large as 5 cm in diameter. So I think that as people
are starting to propose these therapies as curative therapy in opera-
tive candidates, it is important that we evaluate them and determine
their limitations.
In his presidential address at this meeting, Dr Craig Miller em-
phasized the importance to cardiothoracic surgeons of training
and participating in such novel nonsurgical therapies. He proposedardiovascular Surgery c Volume 137, Number 1 165
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Ta revision to the cardiac training program that would allot almost
equal time to surgical training and to novel, catheter-based therapy.
At the University of Pittsburgh, we have a hybrid operating room
where we do procedures such as RFA, and it is an integral part of
our training program. I think that it is highly likely in the future
that there will be a subset of patients with early-stage lung cancer
who, after careful staging, will receive adequate treatment with
nonsurgical ablative therapy instead of surgery. For all these rea-
sons, this is a timely report.
The study demonstrated that the therapy was safely adminis-
tered. There were no deaths, hospitalization was less than 24 hours,
and chest tube placement was required in only 8% of patients. It
also demonstrated maintenance of pulmonary function after ther-
apy, and 3-year progression-free survival was 58%. Overall, how-
ever, there was a 31.5% local recurrence rate, despite a relatively
small mean tumor diameter of 2 cm. In fact, tumors larger than 3
cm had a 50% local recurrence rate.
Dr Lanuti, you have discussed the difficulty in assessing these
patients in terms of response to therapy and also recurrence rate,
and that brings me to my first question. Please comment in a little
more detail on how you have addressed posttreatment follow-up?
You did use CT scans and PET scans. Did you find concordance
between those two studies, and to what extent did you confirm
your suspected recurrence with needle biopsy?
Dr Lanuti. All recurrences were confirmed by imaging studies
and, on a single occasion, transthoracic needle biopsy. Methods of
local recurrence detection included diagnostic CT and fluorodeox-
yglucose PET, with relative comparisons among the studies with
time. We found 9 of the 12 recurrences in less than 6 months. I think
that CT and PET alone are not as valuable as they are together. Pa-
tients did not routinely undergo biopsy to confirm the radiograph-
ically determined recurrence. No other modalities were used for
detection of local recurrence.
Dr Christie. Our experience at Pittsburgh with both RFA and
stereotactic radiosurgery has been that postoperative imaging can
be hard to interpret. We too have been using PET and CT, and often
we will take the first posttreatment study as a baseline to compare
other studies. We have been liberal with the use of biopsy, however,
especially as we are trying to ascertain what the imaging means.
For my second and final question, I noted that fully a third of the
patients did not have successfully local control. Do you have any
ideas in terms of how either your technique or the technology might
allow us to improve those outcomes? Thank you for allowing me to
review your article.
Dr Lanuti. Thank you, Dr Christie, for your comments. I will
address your last question; that is, why do we have such a high re-
currence rate, and where does that stand among the other observa-
tional studies? In fact, the recurrence rate in our study falls within
the range observed (3%–42%). Three of the local recurrences were
tumors larger than 3 cm. We learned as the experience matured that166 The Journal of Thoracic and Cardiovascular Suthe Covidien cluster electrode has clear size limitations. The limi-
tations of RFA electrode technology are tumor size, proximity to
blood vessels (because they are heat sinks), and the central nature
of the tumor. Although we have treated a single central tumor
with RFA, in general, the tumors selected for this modality have
been peripheral. We had 2 local recurrences resulting from a proce-
dure-related pneumothorax that allowed the lung to move away
from the electrode, because this particular device doesn’t have
the anchoring tines present in the Boston Scientific electrode. Of
note, we had 2 late recurrences, one at 12 months and one at 17
months. The 17-month recurrence was in a patient with previous
lung cancer who refused surgery. His treatment failed at 17 months
after RFA, and he ultimately went to surgery for a salvage right up-
per lobectomy. His final pathologic report showed a 1-cm residual
adenocarcinoma (T1N0) with extensive hyaline fibrosis consistent
with treatment effect.
In summary, our patient population was a heterogeneous group,
similar to all the observational studies previously published. Care-
ful patient selection and understanding the limitations of the tech-
nology will ultimately reduce the recurrence rate. Although our
study population was small, analysis suggests that tumors larger
than 2 cm are more likely to recur locally after RFA with the Covi-
dien cluster electrode.
Dr Bryan FitchMeyers (St Louis, Mo). Dr Lanuti, there is a di-
rect overlap in the indications for this with stereotactic radiation
therapy If I were a patient with inoperable disease, it would just
seem more appealing to get three doses of 20 cGy as an outpatient
rather than having something stuck in my chest. Could you tell me
what the selling points are to a patient to have RFA rather than ste-
reotactic radiation therapy?
Dr Lanuti. That is a good, pertinent, germane question. It is
easy at Massachusetts General in Boston, because we don’t have
any of these CyberKnife or stereotactic radiosurgery programs,
so often we would have to refer them to another institution. That
is an easy answer. Really, though, you are absolutely right; it is
a competitive modality for surgery. I would say that stereotactic ra-
diosurgery does require some interventions. Fiducial markers have
to be placed bronchoscopically, so that it is a procedure. It is three
separate treatments, although relatively benign, as opposed to RFA,
which is a single treatment and then follow-up with multiple scans
and a 23-hour hospital stay. The late complications of stereotactic
radiosurgery in North America relative to Japan as it is emerging
is that the central lesions have much more likelihood of radiation
pneumonitis and bronchial stenosis, and probably Dr Christie could
comment more than I about their own experience. But there are
limitations. So side by side, these modalities would have to be
compared. I think they don’t have to be considered mutually exclu-
sive but actually potentially complementary; RFA is good for cen-
tral necrosis, whereas these external beam radiotherapy techniques
are good for peripheral type treatment.rgery c January 2009
